Associate Professor MD Ph.D Doru Paul
Weill Cornell Medicine, New York, USA
Dr. Paul has a strong background as a translational and clinical researcher. Since 2003, he has been Principal Investigator or Local Principal Investigator on more than 40 studies, and co-Principal Investigator on 20 others. He has designed and conducted several investigator-initiated studies and initiated 3 FDA-approved investigational new drug studies. He designed the first in-man pilot study that uses Fluorodeoxyglucose (FDG) for the targeted treatment of cancer, obtaining approval from the FDA and funding from the Northwell Health Cancer Institute.
Residency, Internal Medicine, Albert Einstein College of Medicine, Bronx, New York, 1996-99
Fellowship, Hematology Oncology, Montefiore Hospital, New York, New York, 1999-2002
Dr. Paul received his MD from the Carol Davila Faculty of Medicine in Bucharest, Romania in 1993. At the Faculty of Paris 7, in 1995 he received his Clinical Oncology Diploma and in 1996 he received his Chronobiology Diploma and a Masters Degree in the Biology of Aging from the Faculty of Paris 6. In 2016, Dr. Paul received a PhD summa cum laude in Personalized Clinical Oncology, from the Faculty of Medicine in Craiova, Romania. Following his internal medicine residency at the Jacobi Hospital in the Bronx, he completed a hematology and medical oncology fellowship at Montefiore Hospital in 2002.
He was a junior faculty member at Weill Cornell Medical College from 2003-2012 when he served as an Attending Physician in Hematology-Oncology at Lincoln Medical and Mental Health Center.
Between 2012 and 2018, he was an Assistant Professor of Medicine at the Northwell Hofstra School of Medicine and an Attending Physician at the Northwell Health Monter Cancer Center. He was also an Assistant Professor at the Feinstein Institute for Medical Research (2017 – 2018).
Since 2018 he is an Associate Professor at Weill College of Cornell University.